On a day when health insurers were reeling from the Trump administration proposing minimal increases to Medicare Advantage (MA) rates next year and a tightening of risk adjustment rules, a top CMS ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Medicare picks Botox and Trulicity for latest round of negotiations The Centers for ...

The Trump administration has unveiled 15 new drugs selected for a Medicare drug price negotiation program that allows the ...

The Trump administration released the next 15 drugs subject to Medicare price negotiation, including for the first time ...

Investors betting on a Medicare Advantage windfall just got a jolt. Shares of major health insurers sank on Tuesday after the ...

The Trump administration on Tuesday announced the 15 drugs selected to participate in the newest round of the Medicare Drug ...

Why did UnitedHealth stock fall 20%? What did President Trump say about 2027 Medicare Rates? What does a UnitedHealth stock crash mean for patients and investors?

Lower prices from the third round of talks among Medicare and manufacturers will be announced in the fall but won’t go into ...

The drugs up for price negotiations include cancer and diabetes drugs, as well as medications for Crohn's disease, ulcerative colitis and rheumatoid arthritis.

CMS will negotiate the prices for Trulicity, Biktarvy and 13 other high-cost medications commonly covered by Medicaid Parts B and D, according to a Jan. 27 news release from the agency.  The Medicare ...

Jan 26 (Reuters) - The U.S. has ‌proposed ​an average rate increase of 0.09% ‌in payments to private insurers next year for ...

Shares of large Medicare plan providers Humana, CVS Health and UnitedHealth Group plunged in extended trading.